Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Innate Pharma (IPH)
Price€1.75Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | €9.0M | €20.1M | €61.6M | €57.7M | €24.7M | €69.8M | €85.8M | €94.0M | €44.0M |
| Research & development | €43.6M | €52.0M | €56.0M | €51.7M | €47.0M | €49.7M | €78.8M | €69.6M | €67.0M |
| Operating expenses | €63.0M | €71.7M | €74.3M | €74.1M | €72.5M | €68.7M | €104.6M | €87.7M | €84.0M |
| Operating income | −€54.0M | −€51.6M | −€12.7M | −€57.4M | −€47.8M | €1.1M | −€27.1M | €5.1M | −€40.0M |
| Operating margin | −599.76% | −256.32% | −20.55% | −99.57% | −193.60% | 1.55% | −31.52% | 5.48% | −90.80% |
| EBITDA | −€52.6M | −€49.6M | −€7.6M | −€12.0M | −€43.2M | €57.9M | −€10.5M | €12.5M | −€35.6M |
| EBITDA margin | −584.39% | −246.44% | −12.29% | −20.84% | −174.99% | 82.95% | −12.26% | 13.36% | −80.82% |
| Net income | −€49.2M | −€49.5M | −€7.6M | −€58.1M | −€52.8M | −€64.0M | −€20.8M | €3.0M | −€48.4M |
| Net profit margin | −546.11% | −245.87% | −12.28% | −100.74% | −213.78% | −91.70% | −24.19% | 3.25% | −109.88% |
| Basic EPSper basic share | -€0.55 | -€0.61 | -€0.09 | -€0.73 | -€0.66 | -€0.81 | -€0.31 | €0.05 | -€0.89 |
| Diluted EPSper diluted share | -€0.55 | -€0.61 | -€0.09 | -€0.73 | -€0.66 | -€0.81 | -€0.31 | €0.05 | -€0.89 |